DURECT Corporation (DRRX) Shares Up 5.6%
Shares of DURECT Corporation (NASDAQ:DRRX) shot up 5.6% on Monday . The stock traded as high as $1.87 and last traded at $1.87. 615,610 shares changed hands during mid-day trading, an increase of 7% from the average session volume of 573,044 shares. The stock had previously closed at $1.77.
A number of brokerages recently issued reports on DRRX. ValuEngine raised DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and raised their price target for the stock from $1.25 to $3.00 in a research note on Wednesday, July 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a research report on Sunday, June 25th.
The stock has a 50-day moving average price of $1.66 and a 200 day moving average price of $1.38. The firm’s market cap is $308.70 million.
DURECT Corporation (NASDAQ:DRRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). The company had revenue of $4.32 million during the quarter, compared to the consensus estimate of $5.17 million. DURECT Corporation had a negative return on equity of 629.35% and a negative net margin of 221.01%. Equities research analysts predict that DURECT Corporation will post ($0.21) EPS for the current year.
A number of institutional investors have recently made changes to their positions in DRRX. Teachers Advisors LLC increased its holdings in DURECT Corporation by 16.0% in the fourth quarter. Teachers Advisors LLC now owns 224,361 shares of the specialty pharmaceutical company’s stock valued at $301,000 after buying an additional 31,001 shares during the last quarter. Wells Fargo & Company MN raised its stake in DURECT Corporation by 152.3% during the first quarter. Wells Fargo & Company MN now owns 381,802 shares of the specialty pharmaceutical company’s stock valued at $400,000 after buying an additional 230,500 shares in the last quarter. SG Americas Securities LLC bought a new position in DURECT Corporation during the 1st quarter worth approximately $147,000. TIAA CREF Investment Management LLC lifted its holdings in DURECT Corporation by 2.2% during the 1st quarter. TIAA CREF Investment Management LLC now owns 423,625 shares of the specialty pharmaceutical company’s stock worth $445,000 after buying an additional 9,289 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in DURECT Corporation by 2.6% during the 1st quarter. Geode Capital Management LLC now owns 985,630 shares of the specialty pharmaceutical company’s stock worth $1,034,000 after buying an additional 24,869 shares during the last quarter. 45.82% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “DURECT Corporation (DRRX) Shares Up 5.6%” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/04/durect-corporation-drrx-shares-up-5-6.html.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Stock Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related stocks with our FREE daily email newsletter.